

AACR 2025 Annual Meeting: Ludwig Community Poster Sessions

Poster session date		Session type - Location	Poster title	Ludwig location	Presenter/Ludwig PI	Session time (U.S. EDT)
4/27/2025	Where's Waldo: Spatial Complexity of the Tumor Microenvironment 1	Section 7	Spatial heterogeneity of tumor cell states in primary cutaneous melanoma	Ludwig Harvard	Tuulia Vallius/Peter Sorger	Evening Session 2-5 PM
4/27/2025	Comprehensive Multiomic Profiling of Chromatin Dynamics, DNA Methylation, and Tumor Microenvironments	Section 9	Epigenomic dissection of histology-specific drivers of testicular germ cell tumors	Ludwig Harvard	Esmé Wheeler/Myles Brown	Evening Session 2-5 PM
4/27/2025	Late-Breaking Research: Tumor Biology 1	Late-Breaking Poster Session - Section 53	Decoding systemic circadian regulation across multi-tissues in response to tumor stress	Ludwig Harvard	Chuqian Liang/Myles Brown	Evening Session 2-5 PM
4/27/2025	Drug Resistance in Molecular Targeted Therapies 1	Section 19	Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by replication stress-induced genomic instability and mitotic cell death	Ludwig Harvard	Chendi Li/Aaron Hata	Evening Session 2-5 PM
4/27/2025	Combination Immunotherapies	Section 28	Targeting TET3 potentiates an effective anti-tumor immune response after irradiation	Ludwig Chicago	Sera Averbek/Stephen Kron	Evening Session 2-5 PM
4/27/2025	Spatial Proteomics and Transcriptomics 1	Section 32	Spatial transcriptomic characterization of uterine carcinosarcomas identifies MECOM as a tumor regulator	Ludwig Chicago	Katherine Kurnit/Ernst Lengyel	Evening Session 2-5 PM
4/27/2025	Imaging in Animal Models	Section 3	Real time imaging of the non-small cell lung cancer immune microenvironment modulation by low dose photodynamic therapy	Ludwig Lausanne	Damien Marie/Johanna Joyce	Evening Session 2-5 PM
4/27/2025	Stem Cells, Development, and Cancer	Section 5	Decoding developmental programs driving tumorigenesis and immunotherapy resistance in triple-negative breast cancer	Ludwig Stanford	Rachel Gleyzer/Aaron Newman	Evening Session 2-5 PM
4/27/2025	Where's Waldo: Spatial Complexity of the Tumor Microenvironment 1	Section 7	High-resolution profiling of the tumor microenvironment with spatial ecotypes	Ludwig Stanford	Wubing Zhang/Aaron Newman	Evening Session 2-5 PM
4/28/2025	Application of Bioinformatics to Cancer Biology	Section 44	Improved non-invasive gene expression inference using advanced machine learning	Ludwig Stanford	Amirsaman Ashtari/Ash Alizadeh	Morning Session 9 AM - 12 PM

4/28/2025	Liquid Biopsy: Circulating Nucleic Acids 5 / Circulating Tumor Cells 2	Section 28	Enhanced detection of pancreatic cancer through methylation-based liquid biopsy: insights into tumor heterogeneity, early alterations, and stromal contributions	Ludwig Stanford	Rui Wang/Ash Alizadeh	Morning Session 9 AM - 12 PM
4/28/2025	Metabolic Dependencies	Section 14	Targeting oxygen consumption with metformin and phenformin have differential effects on immune cells in the tumor microenvironment	Ludwig Weill Cornell	Sadna Budhu/Jedd Wolchok, Taha Merghoub	Morning Session 9 AM - 12 PM
4/28/2025	Digital Pathology	Section 46	Advancing multimodal machine learning techniques to predict platinum resistance in high-grade serous ovarian cancer	Ludwig Chicago	Leonhard Donle/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Digital Pathology	Section 46	Using digital pathology to differentiate survival phenotypes in high-grade serous ovarian cancer	Ludwig Chicago	Kelsey Goon/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression	Section 38	Inhibiting NNMT in cancer-associated fibroblasts reduces immunosuppression	Ludwig Chicago	Janna Heide/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Drug Combination Strategies for Cancer Treatment	Section 19	Navitoclax, a Bcl-2/xL inhibitor, and YM155, a survivin inhibitor, in combination with carboplatin effectively inhibit ovarian cancer tumor growth	Ludwig Chicago	Tejas Samantaray/Ernst Lengyel	Morning Session 9 AM - 12 PM
4/28/2025	Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 1	Section 35	Combined anti-CSF-1R and anti-TIM-3 overcome immune-mediated mechanisms of PARP inhibitor (PARPi) resistance in BRCA1-associated triple negative breast cancer	Ludwig Harvard	Adam Nelson/Jennifer Guerriero	Morning Session 9 AM - 12 PM
4/28/2025	Cancer Evolution In Response to Therapy	Section 2	Chemotherapy enriches one of two pre-existing coordinated cellular programs characterized by inflammatory and stress pathways in high grade serous ovarian cancer	Ludwig Harvard	Nomeda Girnius/Joan Brugge	Morning Session 9 AM - 12 PM
4/28/2025	Novel Drug Resistance Mechanisms	Section 22	Fumarylacetoacetate hydrolase (FAH) stimulates resistance to CDK4/6 inhibitors in hormone receptor-positive breast cancer via a novel non-canonical function	Ludwig Harvard	Jenny Hogstrom/Gerburg Wulf	Evening Session 2-5 PM
4/28/2025	Aging and Senescence in the Tumor Microenvironment	Section 2	Cell populations in human breast cancers are molecularly and biologically distinct with age	Ludwig Harvard	Adrienne Parsons/Peter van Galen	Evening Session 2-5 PM
4/29/2025	Pediatric Cancer Models	Section 5	Development of immunocomplex pediatric tumor organoids for onco-immunotherapy research	Ludwig Stanford	Naiara Martinez Velez/Crystal Mackall	Morning Session 9 AM - 12 PM
4/29/2025	Liquid Biopsy: Circulating Nucleic Acids 2	Section 29	CANARY-TF: an improved copy number and tumor fraction estimator for liquid biopsy applications	Ludwig Stanford	Diego Almanza/Maximilian Diehn	Morning Session 9 AM - 12 PM

4/29/2025	Angiogenesis	Section 1	BNIP3-dependent muscle atrophy in cancer cachexia promotes PDAC progression	Ludwig Chicago	Alexandra Sophia Ware/Kay Macleod	Morning Session 9 AM - 12 PM
4/29/2025	Integrating Chromatin, Oncogenes, DNA Repair, and Biomarkers for Therapeutic Advancements	Section 11	PARP1 and EZH2 independently limit 5'-3' end resection to promote rapid DNA repair after radiation	Ludwig Chicago	Elena Efimova/Stephen Kron	Morning Session 9 AM - 12 PM
4/29/2025	Metabolic Pathways	Section 13	Regulation of metabolic programming in esophageal cancer by transcription factor p63	Ludwig MIT	Niamh McNamee/Matthew Vander Heiden	Morning Session 9 AM - 12 PM
4/29/2025	Metabolic Pathways	Section 13	Cancer cells exhibit novel metabolic vulnerabilities when exposed to low lipid environments	Ludwig MIT	Diya Ramesh/Matthew Vander Heiden	Morning Session 9 AM - 12 PM
4/29/2025	Kinases/Phosphatases, Ubiquitin, and Ubiquitin-like Proteins	Section 12	The causes and consequences of off-target activation of the GCN2-eIF2a-ATF4 axis in cancer therapy	Ludwig MIT	C. Ryland III/Matthew Vander Heiden	Morning Session 9 AM - 12 PM
4/29/2025	Liquid Biopsy: Circulating Nucleic Acids 2	Section 29	Enhancing circulating tumor DNA recovery and liquid biopsy sensitivity with precision liposomal priming agents	Ludwig MIT	Kasturi Chakraborty/Sangeeta Bhatia	Morning Session 9 AM - 12 PM
4/29/2025	Cancer Cell Heterogeneity, Evolution, and Trajectory Profiling	Section 3	Comprehensive analysis of somatic mutagenesis in normal tissues across 19,643 samples reveals insights into clonal evolution and tumorigenesis	Ludwig Harvard	Leonie Stockscläder/Chris Sander	Morning Session 9 AM - 12 PM
4/29/2025	Late-Breaking Research: Clinical Research 2 / Endocrinology	Late-Breaking Poster Session - Section 51	A transcriptomic signature predicts mortality risk and immune checkpoint inhibitor response beyond molecular and morphological features in lung adenocarcinoma from never smokers	Ludwig Chicago	Wei Zhao/Lixing Yang	Morning Session 9 AM - 12 PM
4/29/2025	Late-Breaking Research: Clinical Research 2 / Endocrinology	Late-Breaking Poster Session - Section 51	Novel performance quantification of MCED testing to aid clinical decisions: Analysis of a sequential reflex blood-based methylated ctDNA test	Ludwig Harvard	Hutan Ashrafian/Franziska Michor	Morning Session 9 AM - 12 PM
4/29/2025	Reversal of Drug Resistance 2	Section 23	SIRT5 promotes chemoresistance through metabolic rewiring for nucleotide replenishing in refractory triple negative breast cancer	Ludwig Harvard	Zuen Ren/Marcia Haigis, Leif Ellisen	Morning Session 9 AM - 12 PM
4/29/2025	Phase II and Phase III Clinical Trials in Progress	Section 51	Tagraxofusp plus venetoclax and azacitidine in patients ineligible for intensive chemotherapy with previously untreated CD123+ acute myeloid leukemia: A phase 2 multicenter trial	Ludwig Harvard	Alessandra Tosolini/Andrew Lane	Evening Session 2-5 PM
4/29/2025	Phase II Clinical Trials 2	Section 50	Fibroblast growth factor receptor (FGFR) inhibition demonstrates anti-tumor activity in succinate dehydrogenase deficient gastrointestinal stromal tumor (SDHd GIST)	Ludwig Harvard	Priscilla Merriam/Bradley Bernstein	Evening Session 2-5 PM
4/29/2025	A Role for the Tumor Microenvironment in Progression	Section 1	Decoding tumor intrinsic and stroma-related drug resistance in EGFR mutant NSCLC	Ludwig Harvard	Radhika Koranne/Aaron Hata	Evening Session 2-5 PM

4/29/2025	Drug Resistance in Molecular Targeted Therapies 4	Section 18	Single-cell and spatial approaches of identifying targets in endocrine therapy-resistant breast cancer	Ludwig Chicago	Svetlana Semina/Geoffrey Greene	Evening Session 2-5 PM
4/29/2025	Development of Chemopreventive Agents and Preclinical Models	Section 48	Zeaxanthin augments CD8+ effector T cell function by enhancing TCR stimulation	Ludwig Chicago	Freya Zhang/Chuan He	Evening Session 2-5 PM
4/29/2025	Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators	Section 37	PLT012, a humanized CD36-blocking antibody, is effective for unleashing anti-tumor immunity and against liver metastasis	Ludwig Lausanne	Yi-Ru Yu/Ping-Chih Ho	Evening Session 2-5 PM
4/29/2025	CAR Therapies: Emerging Approaches and Combinations	Section 38	Generation of multi-specific CAR T cells using a novel single-marker selection platform to target medulloblastoma heterogeneity	Ludwig Stanford	Diren Usta/Crystal Mackall	Evening Session 2-5 PM
4/30/2025	Identification of New Cancer Vulnerabilities Through Convergence Science	Section 45	Germline-p53-mutant adrenocortical carcinoma is a possible candidate for the novel use of arsenic trioxide as a first targeted anticancer therapy for Li-Fraumeni Syndrome	Ludwig Oxford	Neha Wali/Xin Lu	Morning Session 9 AM - 12 PM
4/30/2025	Metabolism and Signaling	Section 11	ATF4 is required for PanIN formation and PDAC via effects on nucleotide metabolism and suppression of p53 activity	Ludwig Chicago	Leah M. Ziolkowski/Kay Macleod	Morning Session 9 AM - 12 PM
4/30/2025	Identification of New Cancer Vulnerabilities Through Convergence Science	Section 45	Metabolic mechanisms underlying late recurrence in hormone receptor positive breast cancer	Ludwig Harvard	Bryce Ordway/Leif Ellisen	Morning Session 9 AM - 12 PM
4/30/2025	Vesicles in the Tumor Microenvironment	Section 6	HD-PTP modulates anti-tumor immunity via extracellular vesicles in triple-negative breast cancer	Ludwig Harvard	Chenxu Guo/Leif Ellisen	Morning Session 9 AM - 12 PM
4/30/2025	Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1	Section 32	High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlates of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer	Ludwig Harvard	Alexander Gottlieb/Jennifer Guerriero	Morning Session 9 AM - 12 PM
4/30/2025	Drug Resistance in Molecular Targeted Therapies 5	Section 18	Elucidating mechanisms of cancer cell persistence to lorlatinib in ALK positive NSCLC	Ludwig Harvard	Toshio Fujino/Aaron Hata	Morning Session 9 AM - 12 PM
4/30/2025	Immune Monitoring / Clinical Correlates	Section 31	Unravelling temporal dynamics of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma through comprehensive single-cell and multi-omic profiling	Ludwig Stanford	Yiyun Chen/Crystal Mackall	Morning Session 9 AM - 12 PM